English | 简体中文 | 繁體中文 | 한국어 | 日本語
  Press Releases
Wednesday, January 12, 2022
冠科美博 (Apollomics Inc.) 将于 2022 年 1 月 26-27 日(周三、周四)举办线上投资者活动
冠科美博 (Apollomics Inc.) 將於 2022 年 1 月 26-27 日(週三、週四)舉辦線上投資者活動
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022
Tuesday, January 4, 2022
冠科美博(Apollomics)首席执行官余国良博士当选为百华协会 (BayHelix Group) 董事会主席
冠科美博(Apollomics)首席執行官余國良博士當選為百華協會 (BayHelix Group) 董事會主席
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group
Monday, November 22, 2021
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用于治疗复发或难治性急性髓系白血病的中国 III 期临床试验第一例受试者成功入组
冠科美博(Apollomics)Uproleselan 注射液(APL-106)用於治療復發或難治性急性髓系白血病的中國 III 期臨床試驗第一例受試者成功入組
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Friday, October 1, 2021
Edison Oncology和冠科美博(Apollomics)宣布EO1001(APL-122) I/IIa 期臨床試驗中首例患者接受治療

Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | Beijing: +86 400 879 3881 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575